Nephrocare Health Services Share Price
705.65-1.10 (-0.16%)
+49.74% past 1 Year
Nephrocare Health Services is engaged in offering comprehensive dialysis care through its network of clinics - from diagnosis to treatment and wellness programs including haemodialysis, home and mobile dialysis, supported
Corporate filings & documents
Announcements
We hereby inform that the Company has approved grant of ESOPs under the Scheme as per the disclosure annexed herewith.
1 day agoWe hereby inform that the Company has approved grant of ESOPs under the Scheme as per the disclosure annexed herewith.
1 day agoPursuant to Reg 30 of SEBI Listing Regulations we wish to hereby inform that NephroPlus Health Services Kazakhstan LLP an overseas subsidiary of the Company has entered into a Share Purchase Agreement for acquisition of 100% participatory interest in Dialysis Center Almaty LLP in Kazakhstan as per the disclosure annexed herewith.
2 days agoPursuant to Regulation 30 of SEBI Listing Regulations we hereby inform that the Company has received Tax demand pursuant to Tax Audit as per the annexed disclosure.
3 days agoPursuant to Regulation 30 of SEBI Listing Regulations we hereby inform that the Company has received Tax demand pursuant to Tax Audit as per the annexed disclosure.
3 days agoPlease find enclosed herewith Transcripts for the investors Earning call held on August 12 2026.
2 weeks agoPlease find enclosed herewith Transcripts for the investors Earning call held on August 12 2026.
2 weeks agoPursuant to Reg 30 of SEBI Listing Regulations we hereby inform that Nephrocare Health Services Phillipines Inc. a step-down wholly-owned subsidiary of the Company has acquired a dialysis centre and has executed an ATA as per the disclosure annexed herewith.
2 weeks agoPursuant to Reg 30 of SEBI Listing Regulations we hereby inform that Nephrocare Health Services Phillipines Inc. a step-down wholly-owned subsidiary of the Company has acquired a dialysis centre and has executed an ATA as per the disclosure annexed herewith.
2 weeks agoDeclartion of voting results along with scrutinizers report of the 17th AGM of the Company.
3 weeks agoDeclartion of voting results along with scrutinizers report of the 17th AGM of the Company.
3 weeks agoPursuant to Reg 30 of the SEBI Listing Regulations we hereby inform you that the Company has scheduled an investor conference call as per the disclosure annexed herewith.
3 weeks agoPursuant to Reg 30 of the SEBI Listing Regulations we hereby inform you that the Company has scheduled an investor conference call as per the disclosure annexed herewith.
3 weeks agoPursuant to Reg 30 of SEBI Listing Regulations we hereby inform that Nephrocare Health Services Phillipines Inc. an overseas stepdown wholly-owned subsidiary of the Company has acquired a Dialysis centre and has executed an Asset Transfer Agreement as per the disclosure annexed herewith.
3 weeks agoPursuant to Reg 30 of SEBI Listing Regulations we hereby inform that Nephrocare Health Services Phillipines Inc. an overseas stepdown wholly-owned subsidiary of the Company has acquired a Dialysis centre and has executed an Asset Transfer Agreement as per the disclosure annexed herewith.
3 weeks agoClarification to disclosure under Reg 30 dated May 26 2026 regarding incorporation of Nephrocare Services Kazakhstan LLP.
3 weeks agoClarification to disclosure under Reg 30 dated May 26 2026 regarding incorporation of Nephrocare Services Kazakhstan LLP.
3 weeks agoSummary of proceedings of the 17th AGM of the Company.
3 weeks agoSummary of proceedings of the 17th AGM of the Company.
3 weeks agoIn Continuation to our letter dated July 24 2026 please find enclosed link of the audio recording of the Investors Conference Call held on August 12 2026 on the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2026
3 weeks agoIn Continuation to our letter dated July 24 2026 please find enclosed link of the audio recording of the Investors Conference Call held on August 12 2026 on the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2026
3 weeks agoPursuant to Reg 32 of SEBI Listing Regulations read with Reg 41 of SEBI ICDR Regulations please find enclosed herewith Monitoring Agency Report for quarter ended June 30 2026.
3 weeks agoPursuant to Reg 32 of SEBI Listing Regulations read with Reg 41 of SEBI ICDR Regulations please find enclosed herewith Monitoring Agency Report for quarter ended June 30 2026.
3 weeks agoPlease find attached the outcome of Board meeting held on August 11 2026.
3 weeks agoPlease find attached the outcome of Board meeting held on August 11 2026.
3 weeks agoPress release on Un-audited standalone and consolidated financial results for the quarter ended June 30 2026.
3 weeks agoPress release on Un-audited standalone and consolidated financial results for the quarter ended June 30 2026.
3 weeks agoPlease find attached investor presentation for quarter ended June 30 2026.
3 weeks agoPlease find attached investor presentation for quarter ended June 30 2026.
3 weeks agoUn-audited standalone and consolidated financial results for the quarter ended June 30 2026.
3 weeks agoUn-audited standalone and consolidated financial results for the quarter ended June 30 2026.
3 weeks agoPursuant to Regulation 30 of SEBI Listing Regulations we hereby inform you that the Company has scheduled an Investor Conference Call as per the disclosure enclosed herewith.
3 weeks agoPursuant to Regulation 30 of SEBI Listing Regulations we hereby inform you that the Company has scheduled an Investor Conference Call as per the disclosure enclosed herewith.
3 weeks agoPlease find enclosed the Trading Plans dated August 05 2026 received from Designated Persons of the company and same have been approved by the compliance officer.
4 weeks agoPlease find enclosed the Trading Plans dated August 05 2026 received from Designated Persons of the company and same have been approved by the compliance officer.
4 weeks agoPursuant to Regulation 30 of the SEBI Listing Regulations we hereby inform you that the Company has scheduled an Investor Result Conference Call on Wednesday 12th August 2026 at 10:00 A.M IST to discuss the Unaudited Financial Results of the Company for the quarter ended 30th June 2026. A copy of the invitation is also attached for your information
1 month agoPursuant to Regulation 30 of the SEBI Listing Regulations we hereby inform you that the Company has scheduled an Investor Result Conference Call on Wednesday 12th August 2026 at 10:00 A.M IST to discuss the Unaudited Financial Results of the Company for the quarter ended 30th June 2026. A copy of the invitation is also attached for your information
1 month agoNephrocare Health Services Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11-08-2026 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2026.
1 month agoNephrocare Health Services Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11-08-2026 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2026.
1 month agoNewspaper Publication regarding Notice on 17th Annual General Meeting and information on remote e-voting.
1 month agoNewspaper Publication regarding Notice on 17th Annual General Meeting and information on remote e-voting.
1 month agoDispatch of letter providing a web-link of the Annual Report for the FY 2025-26 along with AGM notice.
1 month agoDispatch of letter providing a web-link of the Annual Report for the FY 2025-26 along with AGM notice.
1 month agoNotice of 17th Annual General Meeting of the Company to be held on Wednesday August 12 2026.
1 month agoNotice of 17th Annual General Meeting of the Company to be held on Wednesday August 12 2026.
1 month agoAnnual Report for the FY 2025-26 including Notice of the 17th Annual General Meeting of the Company.
1 month agoAnnual Report for the FY 2025-26 including Notice of the 17th Annual General Meeting of the Company.
1 month agoNewspaper publication titled 17th Annual General Meeting of the Company through Video conferencing / Other Audio Visual Means Cut-Off date information.
1 month agoNewspaper publication titled 17th Annual General Meeting of the Company through Video conferencing / Other Audio Visual Means Cut-Off date information.
1 month agoPursuant to Reg 30 of SEBI Listing Regulations 2015 we hereby inform that the Company has approved allotment of 2 18 297 equity shares of face value of Rs. 2/- each pursuant to the exercise of stock options under the NephroPlus ESOP Scheme 2011.
1 month agoAnnual reports
Concalls & investor presentations
Aug 2026
ConcallPresentation
Aug 2026
ConcallPresentation
May 2026
ConcallPresentation
May 2026
ConcallPresentation
Feb 2026
ConcallPresentation
Feb 2026
ConcallPresentation
Corporate Actions
Date
Type
Details
No data available.
Company details
Registered office
5th Floor, D Block Ilabs Centre, Plot 18, Software Units Layout Survey No. 64, Madhapur, Shaikpet Hyderabad Telangana PIN: 500081 Tel No: 040 4240 8039 Fax No: NULL Email: [email protected] Internet: www.nephroplus.com
Registrars
Karvy Selenium Tower B, Plot 31-32Gachibowli,Financial District, NanakramgudaHyderabad – 500032Tel. No. 040 67161500Fax. No. 040 23001153E-mail: [email protected]: www.karvy.comToll Free No. of exclusive Call Centre:1-800-345001 Karvy Selenium Tower B, Plot 31-32 Gachibowli,Financial District Nanakramguda PIN: Tel No: 040 - 67162222/18003094001 Fax No: NULL Email: [email protected] Internet: www.kfintech.com
Management
Kishore Kathri, Head Legal, Company Secretary & Compliance Officer
Vikram Vuppala, Chairman & Managing Director
Vikram Vuppala, Chairman & Managing Director
Om Prakash Manchanda, Non Executive Independent Director
Hemant Sultania, Non Executive Independent Director
Ajay Bakshi, Non Executive Independent Director
Vishal Vijay Gupta, Nominee Director
Gaurav Sharma, Nominee Director
Sunil Kumar Thakur, Nominee Director
Annette Berit Ingrid Kumlien, Non Executive Independent Director
Details
BSE 544647
NSE NEPHROPLUS
ISIN INE428V01029